Dear Reader,

Make no mistake about it…

Nothing can make you richer, faster, than when a little known biotechnology company develops a breakthrough drug for a disease that offers hope and relief to hundreds of thousands of people.

When Gilead Sciences, for instance, developed its first drug treating human immunodeficiency virus, its stock went on a run from $1.14 to over $56.

When Celgene received FDA approval to market Thalomid to treat rare skin conditions, its stock shot from 80 cents a share to nearly $13 within two years.

And revenues from that drug fed a pipeline that would ultimately drive Celgene’s stock price to more than $75 a share.

Had you known what these companies were up to when these breakthrough drugs were in development – and known just how successful they were in Phase II and Phase III trials – you could have made a killing…

A mere $10,000 investment in each of these stocks would be worth over $1.5 million today – a better than 70-to-1 return on your money.

Of course Celgene and Gilead are not the little-known “discovery” drug companies they once were. They’re now thriving pharmaceutical firms with full drug pipelines… and their stock prices won’t be jumping another 7,000% anytime soon.

But one little company my team and I have been following for some time now appears to be on the verge of the kind of mega gains only a high-flying biotech company can produce…

And the path this company is taking is amazingly similar to that of Celgene and Gilead years ago…

Right now they have a potential breakthrough drug entering Phase III trials that could be the only drug in the marketplace to treat deadly melanoma skin cancer.

In other words, it stopped the spread of melanoma – one of the fastest spreading cancers – dead in its tracks.

Many new drug discovery companies take “short cuts” in Phase II, conducting less stringent “unblinded” tests…hoping to move easily into Phase III so early investors can cash out with profits. Not this company. Their decision to send this drug through a much riskier blinded testing process proves they’re confident this drug works – and they’re looking to be successful over the long term.

It’s a strategy that should pay off nicely. Because the company’s drug enjoyed such great success in the more demanding “blinded” test in Phase II, Phase III trials are “confirmatory,” rather than exploratory – which tends to speed up the approval process as well as increase the chance the drug will gain FDA approval for sale in the marketplace.

When that happens, watch out.

This company’s fortunes will almost certainly soar – along with the fortunes of anyone who bought the stock in advance of the headline making news. Why?

Right now there’s no drug on the market that effectively treats melanoma – by far the most serious type of skin cancer. Which means this company’s drug could be the only one of its kind in the marketplace until at least 2022 – when its proprietary status runs out.

So for more than 13 years, this company could have a stranglehold on treating what is by far the fastest growing cancer, with over 60,000 new cases diagnosed each year. Of those cases, more than 8,000 result in death.

Set aside for a moment the powerful impact this company could have on melanoma sufferers everywhere…

The impact it could have on the wealth of early-in shareholders will be nothing short of mind-boggling.

Look no further than the recent success of Celgene for what could be in store for this little company’s stock price…

Celgene’s drug Thalomid when combined with another drug dexamethasone – the success story that’s helped drive the stock from $9 to $75 over the past five years – treats a much less common blood cancer called “multiple myeloma” …

But according to industry estimates, the market for an effective melanoma drug is three times larger – 20,000 multiple myeloma cases will be diagnosed in 2008 compared to over 60,000 melanoma cases.

That’s why based on our extensive research – and very conservative estimates using standard biotech industry calculations – we anticipate that this little under $10 stock could be trading at $96 a share or better in the 12 to 18 months following FDA approval, expected in early 2009.

That’s a healthy 1,108% gain… enough to turn a $10,000 investment into $120,800, perhaps as quickly as over the course of a few years.

And should this company’s breakthrough drug become the standard treatment for tens of thousands new melanoma cases each year – it will no doubt feed a pipeline of new cancer treatments derived from properties this drug uses to successfully treat cancer.

In other words, this is very quickly shaping into the kind of stock every investor dreams about…

But here’s the thing:

While final Phase III results are expected in early 2009, interim Phase III data should be out the fourth quarter of this year. Should the data suggest the drug can work, institutional investors will start to take notice and the stock will almost certainly soar.

I’ve seen it happen so many times before – how the stock prices of little companies with promising products can take off like a rocket once the right people get to know about it.

I only point this out to you now because – if after reviewing this briefing you decide you want in on this opportunity – I don’t want you to miss out on a penny of the profits we could be in store for.

In just a moment I’ll tell you about a trio of other companies our research team has uncovered recently – stocks that are already well up in the month or two since we recommended them… and could also be set to deliver substantial returns as their proprietary products hit the marketplace soon.

My name is Marc Lichtenfeld. I head up a brand new institutional-style research organization here at Mt. Vernon Research called Access™.

We call the service “Access” because it’s the kind of information and research only hedge fund managers get – and happily pay millions of dollars to see.

I’m talking small-cap and up-start companies that are in what we like to call “the gathering period” – where influential investors, insiders and sector specialists are accumulating substantial positions ahead of breakthrough news and/or product announcements.

Access™ provides you with research and insight into up-and-coming companies you can’t possibly get from any newsletter, alert service or investment “guru.” And certainly not from The Wall Street Journal. This is serious research. We don’t just scan the markets or read over financials.

Every upstart opportunity we consider is put through our highly successful and very grueling “F.I.R.S.T.” analysis.

Right off the bat we take a hard look at the company’s Financials to determine if there’s adequate funding, if there’s a large enough market for the products and what the future revenues will be. After all, a company can develop a wonderful life-saving drug or product – but if there’s little market for the product, how lucrative could it be? So three important factors we examine very carefully are size and scope of the market… the “uniqueness” of the product… and the kind of market share the product can expect to have.

Once the financials pass muster, we begin the long and thorough Interview process.

We talk to the players.

We travel to the company.

We interview the sales people, the CEOs, the production people, company executives, even workers on the floor.

We interview executives at competing companies.

We talk to potential or current customers.

We talk to industry and sector experts.

We talk to our Wall Street contacts – boardroom people, CEOs, fund managers, floor traders – just to get a sense for the market.

Next comes months and months of hardcore Research – where we spend thousands of hours pouring over scientific papers, medical journals, industry reports, industry statistics, commentary, blogs – anything that will help us better understand the product, the market and the potential for the product.

Much of our research effort goes into determining the Safety factor of the product. Why? Because this is where many new and promising medical products get tripped up in the FDA process. Many investors have been burned by companies whose drugs or products clearly work in all phases of testing – but sometimes one small side effect can be enough for a gun shy FDA to withhold its approval.

The final piece of the F.I.R.S.T analysis puzzle is T timing. As shareholders, we want in on the ground floor – but we don’t want our money tied up in a stock that’s not about to move for years. That’s why as part of our research, we look for a catalyst… a series of upcoming events with the potential to move the stock: Pretrial data, financing, potential approvals and so on.

Once everything adds up, we put together a conference call where we invite an impartial industry expert to join us in putting the hard questions to management. And we invite you, and your fellow Access™ subscribers, to listen in.

Very serious stuff.

In fact, we may do six months of in-depth, exhaustive research on a single company… only to discover it doesn’t meet our high standards for Access™ recommendation. (We’ll tell you about those too – just in case you see them “written up” elsewhere – as we have seen… and you’re tempted to buy.)

It’s the kind of research I performed as a senior analyst on Wall Street for the largest and most well-known hedge funds in the world – highly proprietary research these firms paid an estimated $10 million a year to get.

Hedge funds, as you know, seek out highly profitable contrarian-style plays – plays that run against the grain of typical investment funds. So, needless to say, many of the recommendations that emerged from our research ruffled a lot of feathers.

I issued a buy recommendation on Costco when the rest of Wall Street thought limiting gross margins would limit profitability. The stock moved from $43.67 at the time of my published recommendation to $72.68 – tripling the return of the S&P 500 during that time period.

One of my most controversial plays came when I recommended selling Florida real estate giant The St. Joe Company at the height of the real estate boom. I continued to pan the stock, despite receiving death threats from investors not too thrilled with my frank research. Within months, the stock was cut in half.

I also issued a sell recommendation on the P.F. Chang's restaurant chain while most of Wall Street was treating it as a growth stock. My research on the company, and talks with industry insiders, told me the company’s new growth engine was floundering. Meanwhile, the rest of Wall Street was treating it as the next great dining concept. The stock went on to lose 50% of its value.

On the long side, I recommended buying Movado and little-known Dynamic Materials based on my research and information culled from industry insiders. Both stocks jumped over 50% shortly after my recommendation. Another little-known stock I recommended – Evergreen Solar – jumped from $3.60 a share to $6.70 – a 76% gain in less than three months…

I tell you about these not to brag, but to impress on you the kind of results good, old-fashioned, roll-up-your-sleeves kind of research – and a bulging rolodex of highly placed insider contacts – can produce. These and other successes did not come from any of the thousands of hit-or-miss chart reading systems floating around out there. They weren’t based on idle rumors, speculation or “flavor-of-the-day” investments…

They came from months and months of institutional quality research: Digging deep into the company’s numbers, asking management the hard questions, interviewing unbiased industry experts, talking to the company’s customers, suppliers and competition, flying to wherever the company does business and taking a good, hard look at the business in action.

It’s the kind of in-depth, focused and highly objective research my colleagues and I were paid very well to perform. No companies, or their hired-gun investment banks, were footing the bill. The firm that signed my paycheck had no stake in the companies we were researching or recommending. We endured the death threats, often having to hire bodyguards to ensure our safety. Our job was to provide our institutional clients with hardcore, professional, unbiased research and nothing else.

And that’s what we did – sometimes to the detriment of our personal safety… and very often with highly profitable results.

The only difference when it comes to my research with Access™ is, instead of doing it only for the world’s most elite hedge funds, my team and I do it for you.

I’ll tell you more about Access™ and the kind of companies we’re examining in a moment. I’ll also tell you how you can try Access™ for 60 days free of any monetary risk to you through this special membership offer.

But first, I have a very important question to ask you…

If you’re an active investor, how satisfied are you with your current stock portfolio? Are you happy with the returns you’re getting? If you’re shaking your head “no” at those questions, you’re not alone. If you said yes, allow me to pose another question…

How satisfied are you knowing there is – and always has been – a very small circle of insiders who get privileged information long before you ever see it? I’m not talking “buy Microsoft because word on the street is they’re going to beat earnings estimates.”

I’m talking about a situation where a fund trader or industry insider – someone with privileged access – calls a friend and says, “Hey, you might want to take a look at this. A lot of people I know close to this situation are buying this stock now. Here’s why…”

Is it fair? Who’s to say? The insiders I’m talking about – people I know and talk to everyday – have spent their entire careers getting to this “inner circle.” They’re smart. They’re experts in their respective fields. And they know how to make (and keep) friends in the right places. So from that perspective, yes – they’ve earned it.

But does that mean you shouldn’t take advantage of their knowledge and expertise if you had an opportunity to do so?

Absolutely not.

BioMarin, a recent recommendation of mine, was a classic example. The company had a promising drug in Phase III trials that treated a medical condition called Phenylketonuria (PKU) – a disorder characterized by increased amounts of the amino acid phenylalanine in the bloodstream of infants that can lead to mental disabilities.

Wall Street ignored the company, maybe because few analysts could pronounce the condition let alone understand it. But more likely they ignored it because it’s a rare disease that doesn’t get as much media attention and research dollars as widespread diseases like cancer and diabetes.

But my research – and my contacts in the medical field – confirmed this was an important development… the first and only of its kind. What’s more, no other drug company had anything similar in the pipeline, which meant when and if the drug gained FDA approval, there would be no competition whatsoever.

More research confirmed the drug was being “fast-tracked” – which means the FDA will speed up the approval process because of the urgent medical need. It was just a matter of months before there was a very high likelihood that the drug would gain approval.

So I put out a recommendation: Buy BioMarin at $18.35 a share. A few weeks later, news of the drug hit Wall Street. BioMarin soared, hitting our target price of $40 by mid January. Those who followed the recommendation had an opportunity to walk away with solid money-doubling gains in just five months – like John S., from Houston, TX:

“Great call on this stock! Without your recommendation I never would have even heard of this company. I am up 101.75% and will sell half my position on Monday. Please continue to bring these type of picks! I realize that there is always uncertainty around the FDA approval process, but you nailed this one. Again, great job!”

Some did better buying the options, given my suggestion the stock would move quickly once Phase III trials results were announced.

That’s when the letters really started pouring in:

“Last Friday, I sold all 10 BioMarin contracts for $11 each!! Turning my $400 investment into a $11,000 return – a gain of $10.60 per contract!! (Not including the $40 'round trip' for brokerage). Not sure what percentage gain that is but I sure am going to have a great Christmas!”
Jason R., Australia

“Great call, guys! I bought the Jan 09 $17.50 calls at $5.30 in July 07 and sold them today at $19.50. Sweet! Keep up the good work.”
Joe M., Easley, SC

“I decided to go the options route and purchased January 08 calls at $2.10. Sold 40 percent in October for a 57.1% locked in gain. Today I sold the balance for an additional 447.6% gain. Total gain: about 505%.”
Don G., Chester, PA

Again, this is the kind of roll-up-your-sleeve research and information that can have a profound effect on your wealth.

And that’s why we’re excited about what I think is an even bigger opportunity brewing with the little company that’s very close to having the only drug on the market that Phase II tests have shown can stop the spread of melanoma skin cancer in its tracks.
Of course there’s always the chance that this company’s drug doesn’t gain FDA approval. That’s the risk here, of course.

Consider how the drug works…

Cancer cells have greatly reduced anti-oxidant capacity, and therefore sport much higher intrinsic levels of reactive oxygen species (ROS) than normal cells.

When injected, this company’s drug quickly increases oxidative stress beyond their breaking point, causing the cell to, in effect, break apart and die – usually within six hours. (Picture blowing up a rubber inner tube too long with it eventually stressing out and bursting That’s roughly the “effect” this company’s drug has on a melanoma cancer cell…)

And because normal cells can handle increased levels of oxidative stress, the drug has little or no impact on them.

The process that’s been successful on melanoma test patients in Phase II trials could very well be successful on a long line of cancers… because of the drug’s ability to differentiate between cancerous and healthy cells and selectively “kill” the cancerous ones.

Best of all, this type of “selective cell destruction” technology is the company’s own proprietary property – and will be for the next 13 years. Based on my research – melanoma is just one of the cancer types the company could be targeting with this technology in the near future. There’s also talk about testing this proprietary process on hematological (blood), ovarian, breast, prostate and pancreatic cancers as well.

Which means any cancer treatments that are derived from it will be the sole property of this little company.

At the risk of getting ahead of ourselves – imagine what could happen to the stock price of a company hailed by Wall Street as “the greatest hope yet for a cure to cancer!”

Needless to say, the sky would almost certainly be the limit!

Maybe that’s why insiders still own 48% of the stock – and not one of them has sold a single share since the company went public roughly two years ago…

Maybe that’s why the FDA granted this company’s product “orphan drug status” – which provides economic incentives, reduced FDA user fees, FDA assistance with the clinical testing process and market exclusivity rights to drugs that show a high level of promise for treating serious diseases.

As I mentioned before, we’re reserving this opportunity for those who choose to join our brand new Access™ premium research service.

Access™ is not for the average investor.

It’s for serious individuals who understand the value and profit potential of getting institutional quality research on “off the radar” companies on the verge of great things.

As an Access™ subscriber, you can expect six to eight recommendations a year. Many will be like the company I’m talking about today – up-and-coming innovators known only to a privileged few… with breakthrough, in-demand, proprietary products in development… sound management behind it… and championed by investors and insiders with a long history of success.

I’ll also be drawing on my years of contrarian investing experience, including my work as a senior analyst at one of the most sought after research firms. If our research uncovers a stock that’s being ignored by Wall Street for all the wrong reasons – or one that’s getting undue attention when it’s not warranted – my track record shows there’s money to be made there as well.

In short, I have all the resources at hand to bring you precisely the kind of research I provided to some of the best known and successful hedge funds on Wall Street – research they were happy to collectively pay $10 million a year to get.

How much will you pay?

It won’t be millions, of course – but it won’t be cheap either.

As I alluded to earlier, the goal of Access™ is to bring together a very small circle of serious, more sophisticated individuals who are looking for the kind of investment you just can’t find through the typical mainstream ways.

The companies I recommend will come as a result of many months of research, diligence, travel, one-on-one meetings, snooping, favor gathering, even a little arm-twisting here and there. It’s how the business works.

My years in the business have taught me that nothing else – no trading system, no black-box technique – can replace good old-fashioned research, detective work and friends in the right places.

Which brings me to another very important point.

When you receive a recommendation through Access™ – you don’t just get a company name and a “buy” recommendation. Far from it. You will know everything there is to know about that company’s business in my in-depth research report.

And it starts immediately.

The first thing we’ll do once my research is completed and I’ve deemed the company to be a good and viable play, is arrange a conference call with the company and invite you to participate.

This is where we talk to the players, the insiders and company executives. We’ll invite one or more industry experts – potential users of the company’s products. We’ll ask the hard questions and demand honest answers. You’ll know precisely what’s going on with the business, its immediate and future plans, and what to look forward to.

(In fact, you’ll want to be in on the call for our upcoming call with the top players in the company I’ve been telling you about. It’s coming up fast – September 10th. But in order to get in, you need to be signed up as an Access™ subscriber by September 6th at midnight…)

I can’t stress enough to you that Access™ is unlike any other advisory service. With many of our investments it’s a rare opportunity to be one of the earliest of “early-in” investors, where your participation in the future fortunes of the company is more like a “partner” rather than one of millions of shareholders.

The research you’ll see coming from Access™, is precisely the kind of research I was doing on behalf of some of the most prestigious hedge funds in the world. That’s why we considered offering this service to professionals and hedge fund managers for $20,000 a year – a bargain when you consider these firms have been known to pay millions for essentially the same research.

But when I created The Access™ Research Group, it was always my intention for it to benefit regular people – so they could see the kind of research that’s usually reserved for Wall Street’s elite. These insiders have access to millions of dollars worth of resources and information each and every day – isn’t it time you had the same “edge” for a change? Isn’t it time you got the jump on the very folks who have had a long history of being the first in on the very best opportunities the market has to offer?

When I negotiated my arrangement here with Mt. Vernon Research, I made it clear I wasn’t coming on board to be just another newsletter editor… making stock picks just because an upcoming issue demands one.

Not my style. Never has been.

If this arrangement were to work out I’d need a staff of researchers… a generous research budget… the freedom to travel to wherever the next opportunity requires… and use whatever means needed to get the closest-to-the-bone information I can get.

I also wanted Access™ to be more than just cold and impersonal words in print.. That’s why twice a year I’ll extend an invitation to you to join me and my other readers for lunch at the famed Engineer’s Club near my publisher’s office in Baltimore, where I’ll update all of you on everything that’s going on… talk a little shop… and give you some insight into the companies we’re researching.

So when I said it’s quite possible Access™ could cost a million dollars a year or more to operate properly – I fully expected the obligatory “we’ll get back to you.” But that’s not what I heard. Instead I was told, “Tell us what you need. Do what you do best. Don’t worry about costs. We want this to be the best research ever offered to our most valued members.”

So it may not surprise you to know that the cost of a full year of Access™ is $6,000 per year.

But it’s a bargain when you consider and appreciate the pedigree of experts you’ll be aligning yourself with – the access you’ll be getting to industry insiders, market professionals and “close to the bone” information. Not just from my team and I, the people we know. The professionals in our little circle who understand how the system works – how a little favor slipped to us can mean three or four favors in return.

Bottom line, by joining Access™ you’re getting in on the oldest “game” on Wall Street. The one insiders and those with access to privileged information have been playing since men began gathering on that southern Manhattan curb-side in the evenings and auctioning company shares one at a time over 100 years ago.

It’s a game where just a select few get into the very best situations very early on – then wait quietly until the crowd piles on.

That’s the opportunity I’m offering you by joining Access™ today.

And because I want you to be absolutely sure this arrangement works for you, I’m offering you an opportunity to try Access™ membership for the next 60 days at no risk to you. If you decide it’s not for you, simply let us know and we’ll return every cent of your dues.

This way, you’ll get to see how Access™ works – and how it’s different from any investment advisory and research service you’ll ever participate in.

Of course you’ll get my full just-published report on the melanoma drug company we’re so excited about… and all the updates to follow.

Along the way you’ll be constantly updated on what this company is up to – from its Phase III testing progress… to planned marketing efforts… to sales results… to how it’s reinvesting any profits it earns. You’ll also get updates on other drugs in the company’s pipeline (including a rheumatoid arthritis treatment that’s showing early success in preliminary trials.)

(Please don’t underestimate the power of this. Yes, you’ll have an opportunity to buy in very early. But up-start companies like these offer numerous opportunities to take returns ahead of pending news, or when the stock price gets ahead of itself… and buy more on the inevitable dips. That’s what the big hedge funds do – and we’ll show you how. That’s why it’s so important you follow the many updates you’ll receive as an Access™ subscriber on this and other companies.)

Plus you’ll get all the details on three more up-and-coming companies we recently added to our Access™ portfolio – companies we think are capable of matching the potential gains of our exciting new melanoma drug company:

One of the most exciting plays in our current Access™ portfolio is a little company that’s on the cutting edge of non-controversial, non-embryonic stem cell research. It uses a unique process where stem cells are harvested from the patient’s own fat cells and used for, among other things, breast reconstruction in cancer patients. This unique technology has already been approved in Japan and Europe and is likely to apply for FDA approval here in the United States sometime this year.

No question, stem cell research is a huge “untapped” segment of the medical market. Few investors are aware of the progress being made in the area of non-embryonic stem cell harvesting, thanks to billions in private funding and recent government-initiated investments.

Stem cells can be used in spinal fusion, allowing paraplegics to possibly walk again. They can be used in heart muscle repair, disc repair, nerve regeneration, Crohn’s disease, diabetes, bone fractures, tissue damage, skin grafting, meniscus and joint repair and more. In fact, industry estimates suggest there’s a 34.4 million patient market from stem cell products – including 8.45 million cardio vascular procedures alone.

And the market’s just starting to take off. In 2005, stem cell therapy market sales were a mere $900,000. In 2006, revenues jumped nearly 17-fold – to $16 million. In 2007, the market doubled to $36 million – and is expected to more than triple this year to $146 million.

From here, industry sales are projected to essentially double each and every year until 2012, when sales are expected to reach $2.3 billion, according to industry analyst Robin Young.

The little-known company we’re still recommending is already ranked sixth in revenues out of over 200 stem cell research companies, and it’s very much poised to capture a generous share of this fast-growing market.

A big reason there’s so much buzz about this company is because its stem cell harvesting method is less invasive and less painful than typical bone marrow harvesting methods – and yields far more stem cells than the average bone marrow sample.

Plus, its flagship product is already approved in Europe for breast augmentation following a partial mastectomy. More than 2 million women worldwide have breast cancer and over 400,000 cases are eligible for reconstruction, opening up a huge potential market for this company’s non-invasive product.

And it’s very possible that the same product used in breast cancer cases could be used in various types of cosmetic surgery down the road, introducing the market to even greater numbers.

But perhaps the most exciting news is that the company is currently in clinical trials to treat various forms of heart disease. That opens up a huge potential market for this company’s products. Over 20 million Americans have heart disease – and 250,000 of those have chronic ischemia, which is a shortage of blood supply to the heart. Experts are very hopeful that this company’s stem cell research and products could be the long-awaited treatment to the epidemic heart disease problem – not only in the U.S., but around the world as well.

In fact, since we recommended this company just a few months ago, it’s been moving fast-forward with it’s strategy: It’s expanded its patents significantly, and expanded or strengthened partnership agreements with hospitals in Korea, Thailand, Taiwan and Japan.

As I mentioned, this recommendation is already up over 20% since we first recommended it back in May. And keep in mind, the events that we expect to drive the stock higher – mainly FDA approval of its stem cell harvesting process – have yet to happen.

Using our F.I.R.S.T analysis, that puts this little company’s stock price – currently in the high $6 range – at $81 over the next four years.

That means, if you were to take a 5,000-share stake in this little company now, it could be worth over $400,000 before 2012 is out. A 10,000-share stake could very easily mushroom to $810,000 over the same time frame…

Again, this is another company very few regular investors could ever hear about – unless they have access to the kind of research that crosses the desks of big hedge fund managers on a regular basis.

But you'll get our full report on this company once you become an Access™ subscriber – PLUS exclusive online access to our most recent conference call with this company’s officials, where we got some tough questions answered… and learned what the company has planned for the coming year.

Truly, this is a great opportunity not to be missed.

Here’s a recommendation we’re very excited about as well – a tiny little company that’s developed a hand-held cancer detection device that’s been 98% successful in identifying melanoma skin cancer in Phase II testing.

Doctors who have seen and tested the device want it now. And for good reason… because it takes the guess work out of identifying potentially deadly skin cancer during routine check ups.

Here’s the story…

You know from experience that when you go for a physical, one of the first things your doctor does is check your skin for suspicious marks or moles. They use something called the “ABCDE” method, which is an acronym for the various characteristics of a suspect lesion: Asymmetry, Border irregularity, Color variation, Diameter, and whether the area of concern is Evolving over time. Problem is, it’s all visual… highly subjective… and can be easily misdiagnosed by even the best doctors.

This company’s device changes all that in a revolutionary way.

The non-invasive, handheld tool is placed over the lesion and takes images of the affected area as it emits light of various wavelengths. The image is then compared to a database of over five thousand biopsied lesions residing on the company’s servers. In minutes, the doctor receives a “yes or no” report that classifies the patient’s lesion as suspicious for skin cancer or non-suspicious. If suspicious, the doctor will perform a biopsy.

And in a study of 352 lesions, this company’s device correctly diagnosed cancer in 98% of the cases, compared to the 60% to 70% rate doctors are able to identify the disease using the ABCDE method.

So what does this mean? It means doctors will know with near certainty whether or not a lesion should be checked for cancer.

It means fewer patients will have to undergo painful and cost biopsies. It means fewer patients will have to experience the anguish and worry of waiting up to seven days for biopsy results – to learn if they have cancer or not.

Lives will be saved. Skin cancers caught early are nearly 100% treatable. But once the cancer penetrates the skin deeper than two millimeters, it’s usually fatal. When used as part of a routine check up, this company’s device will alert doctors long before the disease can spread.

Of course, looking at it as an investor, I absolutely love it.

I love it because it’s one of those rare, tiny, little companies insiders are not only buzzing about – but they’re buying it up like crazy at today’s market prices. One of the country’s legendary growth company experts – with a 48-year history of snapping up shares of little-known companies with undiscovered potential and growing them into billion-dollar concerns -- has been accumulating a major stake. Many of his super-wealthy friends are getting in on the action as well.

It’s a product that provides an on-going stream of income. Yes, doctors buy the machine at a good price but they have to keep buying proprietary memory cards – one for each patient. And that’s where the bulk of the income will come from. It’s a little like the razor industry: The bulk of Schick’s income is not from the razor they sell you – it’s from the unique razor cartridge refills you need to keep buying afterwards.

It should get another bump when the FDA approves the device for sale.

Then it should see a nice steady climb higher as more and more doctors embrace the technology – not only here in the United States, but ultimately worldwide.

I told you the kind of numbers that could happen with a mere 10% penetration of the roughly 11,000 dermatology clinics around the country. Not withstanding any “mania” buying that may greet this stock once Wall Street catches on to its potential – we could be looking at a $59 stock price before too long – which could mean 880% gains based on today’s prices.

But that’s just the beginning…

Given the low cost of owning this machine (doctor’s cost: around $2,500)… the lives and money it could save patients, doctors, and insurance companies alike… this device could very soon be as common in doctor’s offices as EKG or blood pressure machines.

Should that happen, the numbers could fly off the page! Even when you underestimate profit margins and use standard medical device sector PE ratios, there’s a very real chance this company could ultimately move from its roughly $6 price today – to over $196 a share in the not too far future.

Even though the stock is up substantially since we recommended it roughly four months ago, it’s still a good buy. That’s why the instant you become an Access™ subscriber you’ll have immediate access to the details on this company… and get to hear the conference call – on our website – that we held with company officials a few months back.

But there’s another great opportunity you’ll learn about:

Recently our research uncovered another great biopharmaceutical play – this one an established profit earner whose stock price has been beaten down because one of its main drug products could see competition from a pair of generic drug suppliers.

But what casual observers don’t realize is the company is challenging the effectiveness and safety of the generic competitors given the complexity of the drug and some errors made in the testing process. Should the company prevail and the generic drug makes them have to go back to the drawing board with their drugs, the stock could bounce as much as 35% higher, back to recent highs.

But there’s more to like about this proven drug maker.

It has a very important drug in Phase II testing that has been shown to effectively treat a virus that infects 50% to 80% of the U.S. population by age 40. In addition, the company is very close to adding yet another important drug to growing pipeline by way of an acquisition – one that treats a rare disease that effects over 10,000 people in the U.S. known as HAE. Because of the rarity of the disease, the treatment – if approved – can command as much as $200,000 per patient per year… adding as much as $350 million a year to the company’s revenue stream.

While we’re not targeting the kind of “home run” gains our other recommendations are capable of, this should be a nice “rebound” play in the biopharmaceutical arena – solid profits, great drugs, and a very active pipeline.

In all that’s four solid opportunities awaiting you the instant you become an Access™ subscriber:

• The contrarian biotech play that could double your money in the coming months…
  
  
• The cancer detection device company that could deliver over 880% gains in the short term…
  
  
• The stem cell company that could deliver as much as 1,110% returns over the coming 18 months…
  
  
• And, of course, our latest recommendation – the company with the exciting new drug entering Phase III trials that been shown to target and kill deadly melanoma cancer cells…

Once this drug gains FDA approval, we’re anticipating gains in the 1,100% range – and three-to-five year gains of 5,600% based on this drug’s marketing potential and products currently in the company’s pipeline.

We’ve just completed our research report with all the details on this company, the profit potential, and our strategy for maximizing our gains. You’ll get it as soon as you sign up for your risk-free Access™ membership.

Plus, when you sign up by Saturday September 6th at midnight, you’ll be assured of a spot at our upcoming “discovery” live conference call on this opportunity scheduled for September 10th at 2 p.m EST.

No question, this is a great time to become an Access™ subscriber.

Just the four companies we have waiting for you have the very real potential to turn $10,000 investments into as much as $368,000 in the coming 12 to 18 months… and millions on the longer term as these companies blossom into the Celgene’s and Gilead’s of tomorrow. (Remember, a $10,000 investment early on in just those two companies would be worth well over $1.4 million today…)

Because for the first time ever, it gives everyday people an opportunity to see detailed and painstaking research on little known companies on the verge of great things – long before anyone except for a handful of insiders know about them!

You know, when the big Wall Street hedge funds hired me to research companies, their expectations were clear and their standards were high. They expected the research I delivered to add hundreds of thousands – if not millions – of dollars in profits to their bottom lines.

Our clients understood what all successful investors know: That one great opportunity will always be worth infinitely more than five or six mediocre ones.

I relished the challenge. I live to research companies. To seek out exciting and profitable opportunities. Which is why our firm has gained such a solid reputation for delivering the goods.

That’s the mindset I bring to Access™.

If the idea of having access to the kinds of opportunities I’ve described in this letter interests you, I invite you to join us through this risk free offer.

No one’s more skeptical about any company I set out to research than me. It’s served me well over the years as a Wall Street analyst and researcher. I’ve picked a lot of winners over my 12-year career…made a lot of rich people richer… and investors like you wealthier with my recommendations…

But never have I been this excited about an opportunity – where the potential for gains are so massive – that I’m willing to risk my reputation by telling you today that I firmly believe this little cancer drug company could very well be the “next Celgene.”

If I’m right, it will be a boon for Access™ and a testament to the kind of research we do here…

More importantly, it wcan make you a boatload of cash – the kind of cash that can significantly alter your lifestyle and make for a very happy, secure and very comfortable retirement.

There’s risk, sure. But if you’re willing to take it, my research tells me this is one of those rare opportunities that could pay off very handsomely in the months and years to come.

I’ve been watching this stock the better part of a year now. I’m in touch with company executives… I’ve talked to biotech experts close to the company… I’ve followed this amazing cancer drug through the Phase II trial process. And I can tell you with all certainty – if you’re interested in the kind of potential returns that can literally change your life… then there’s no better time to buy the stock than now.

But you need to hurry. We need you on board by Saturday September 6th at midnight so we can schedule you in for our live September 10th, 2 p.m. EST ‘members only’ conference call.

But there’s an even more urgent reason to become an Access™ subscriber right now…

The biotech industry is especially active in the fall. This is when interest in companies with promising drugs – like the melanoma cancer drug company we’re just now recommending – tends to heat up. The company will be on the road telling their story. Wall Street will start to gain interest once they realize that pivotal Phase III date on this promising drug is just six to nine months away…

Who knows how much higher the stock price could be even as little as a few weeks from now.

And even though the current recommendations you’ll learn about are nicely up since we recommended them to subscribers, I want to stress to you that the events we expect to act as the catalyst for driving the prices much higher have not yet happened. When they do, we fully expect the prices of these stocks to soar as well.

To join now, please or call our VIP Services Team at 888.570.9830 or 410.454.0498 and please mention Priority Code: .

Sincerely,

Marc Lichtenfeld
Founder, Director of Research, The Access™ Research Group

* All claim information has been verified and confirmed as of August 20, 2008.

P.S. To claim your spot for our conference call with this exciting new company who could become the “next Celegene,” please respond to this invitation by midnight on September 6th.

P.P.S. I really want to stress to you how excited I am about the three up-start biopharmaceutical companies I’ve told you about – and the established drug maker, whose stock could be set for a quick money-doubling turn around. Together I’m convinced these four stocks have a very real opportunity to turn a $10,000 investment in each into several hundreds of thousands of dollars in the relative short term – perhaps millions if you hold on to them longer.

P.P.P.S. Remember, you can try a membership to Access™ risk free for the first 60 days. That should give you plenty of time to see the kind of serious, in-depth research we do – the kind hedge fund managers pay millions to get. It’s also enough time to see the stocks we’re recommending… most likely a new recommendation or two… perhaps even see first hand how quickly these stocks can move higher. And in the end, if Access™ is not for you, just let us know before the two months are out and we’ll refund your entire membership cost.